Job ID: 60270

Alzheimer’s Research UK funded PDRA position

Position: Post-doctoral Position

Deadline: 13 October 2021

Employment Start Date: 3 January 2022

Contract Length: 12 months

City: Glasgow

Country: United Kingdom

Institution: University of Strathclyde

Department: Strathclyde Institute of Pharmacy & Biomedical Sciences,


Dementia, of which Alzheimer’s disease (AD) accounts for 60-70% of cases, is a leading cause of disability and dependency worldwide with approximately 50M people suffering from the disease, with this figure estimated to increase dramatically in the coming years primarily due to our increased life expectancy. However, despite these striking statistics, dementia is the only one of the top ten causes of death in the UK that has no treatment that can either cure or slow its progress. Furthermore, the current treatments are limited in their use and primarily offer symptomatic relief rather than targeting the disease itself.  Hence, an intense research effort is underway to better understand the aetiology of AD.  In addition to the widely accepted theory for extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) being involved in AD initiation and progression, there has been a focus on the role of inflammation, with much of this focussed on the role of microglia.  In contrast to the overwhelming evidence that inflammation contributes to disease progression, recent studies in AD resilient patients highlight that the cytokine profile in AD resilient patients is distinct from that observed in cognitively healthy and AD patients and that these altered profiles may contribute to cognitive resilience.

Based on these recent findings, the successful applicant, under the supervision of Trevor Bushell & Shuzo Sakata (Strathclyde Institute of Pharmacy & Biomedical Sciences) & Chris Henstridge (Dundee) will examine whether immunomodulation, rather than immunosuppression, is a therapeutic strategy to promote resilience to AD pathology by determining whether cytokine immunomodulation ameliorates the molecular and synaptic pathology observed in a mouse model of AD.  They will utilize a variety of staining techniques to determine Aβ load in mice following immunomodulatory treatments.  In addition, they will be involved in studies utilising qPCR and array tomography techniques to investigate the inflammatory profile and synaptic pathology present in these mice.

A successful candidate must have a PhD degree in Neuroscience or a related field.  It is desirable if they have experience of in vivo research and immunohistochemistry with knowledge of rodent neuroanatomy being advantageous. You will have an ability to plan and organise your own workload effectively and an ability to work within a team environment. You will have excellent interpersonal and communication skills, with the ability to listen, engage and persuade.

The start date is provisionally 1st January 2022 and is funded by Alzheimer’s Research UK (ARUK) for 12 months.

Informal enquiries can be made directly to Dr Trevor Bushell ( and the deadline for applications is Wednesday 13th October 2021.

To apply for this position, please visit: using Job Ref: 396375.